article Open AccessTop 1% cited
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Annals of Oncology · 2016 · Vol. 28(2) · pp. 368–376
Alexander M. Menzies✉(The University of Sydney)Douglas B. Johnson(Vanderbilt University Medical Center)Sangeetha Ramanujam(The University of Sydney)Victoria Atkinson(Greenslopes Private Hospital)Annie Wong(Peter MacCallum Cancer Centre)John ParkJennifer L. McQuade(The University of Texas MD Anderson Cancer Center)Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center)Katy K. Tsai(University of California, San Francisco)Zeynep Eroglu(Moffitt Cancer Center)Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre)Jessica C. Hassel(Heidelberg University)Jeffrey A. Sosman(Vanderbilt University Medical Center)Alexander Guminski(The University of Sydney)Ryan J. Sullivan(Massachusetts General Hospital)Antoni Ribas(University of California, Los Angeles)Matteo S. Carlino(The University of Sydney)Michael A. Davies(The University of Texas MD Anderson Cancer Center)Shahneen Sandhu(Peter MacCallum Cancer Centre)Georgina V. Long(The University of Sydney)
Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchChronic Lymphocytic Leukemia ResearchMedicineIpilimumabImmunosuppressionPolymyalgia rheumaticaInternal medicineAdverse effectRheumatoid arthritisMelanomaGastroenterologyCancer
MeSH terms
Antineoplastic Agents, ImmunologicalIpilimumabNivolumabAdultAgedAged, 80 and overAntibodies, MonoclonalAutoimmune DiseasesBrain NeoplasmsFemaleHumansMaleMelanomaMiddle AgedRetrospective Studies
Funding
- Cancer Institute NSW
- University of Hong Kong
Citations
814
FWCI
43.66
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Cited by
A review of cancer immunotherapy toxicity
CA A Cancer Journal for Clinicians · 2020 · 1,391 citations
Guidelines of care for the management of primary cutaneous melanoma
Journal of the American Academy of Dermatology · 2018 · 692 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · 2,321 citations
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Mayo Clinic Proceedings · 2019 · 2,172 citations
References
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,554 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,648 citations
Final Version of 2009 AJCC Melanoma Staging and Classification
Journal of Clinical Oncology · 2009 · 4,551 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
New England Journal of Medicine · 2015 · 8,055 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.